ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
MEET YOUR STAFF: Introducing our first Director of Philanthropy, Roberta Plantak
Roberta joined the ALK Positive, Inc. team in March 2026 as our first Director of Philanthropy and has already been making a big difference. We wanted our readers to get to know her more both in her professional capacity, and “behind the scenes”.
-
Patient Perspective: Hope for ALK+ NSCLC Patients
Jeff Sturm reflects on the emotional reality of living with ALK-positive cancer and the role gratitude, kindness, and community can play in helping patients and families hold onto hope.
-
International Patient Spotlight: Vivian McIntyre
Vivian McIntyre shares her journey from Stage IV diagnosis to becoming involved with ALK Positive Canada and finding connection within the global ALK-positive community.
-
Patient Spotlight: Rick Mallick
We interviewed 18-year ALK survivor Rick Mallick about his long journey with ALK+ lung cancer, the wisdom he has gained along the way, what keeps him grounded, and so much more.
-
Clinical Trials Update: TRI-116: Molecular Glue Degraders for Dummies
The ALK-positive community is buzzing about a cutting-edge clinical trial currently recruiting for those with ALK-positive lung cancer. The experimental medication TRI-116 is an ALK molecular glue degrader. A Google search of “molecular glue degrader for cancer” will lead you to terms like proteasome, ubiquitin, and E3 ligase. If your eyes glaze over when you…
-
-
Six Facts About Clinical Research Participation for ALK-Positive Lung Cancer Patients
by Dr. Ken Culver, Executive Director and Medical Director, ALK Positive, Inc.
-
First Patient Dosed in Tri-611 Clinical Trial
The first patient has been dosed in the Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive NSCLC, marking an important step forward in the development of new investigational therapies for the ALK-positive community.
-
Nuvalent Announces Submission of New Drug Application to the FDA for Neladalkib (NVL-655) in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent has officially filed for FDA approval of NVL-655 (neladalkib), a promising next-generation ALK inhibitor for previously treated ALK-positive lung cancer. Backed by results from the ongoing ALKOVE-1 trial, this milestone could bring a powerful new treatment option one step closer for patients facing progression after prior ALK therapies.
-
-
Continuing ALK NSCLC TKI Treatment while on Chemotherapy Leads to Better Outcomes
A recent multi-center study examined outcomes for ALK-positive NSCLC patients who continued their ALK TKI while receiving platinum/pemetrexed chemotherapy after disease progression. The findings suggest that maintaining targeted therapy alongside chemotherapy may improve overall survival and reduce the risk of brain progression in certain patients.
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.